Fulgent Genetics, Inc.
22.73-0.70 (-2.99%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · FLGT · USD
Key Stats
Market Cap
695.74MP/E (TTM)
-Basic EPS (TTM)
-1.66Dividend Yield
0%Recent Filings
8-K
Promising FID-007 trial data
Fulgent Genetics unveiled preliminary phase 2 data on October 20, 2025, showing FID-007 plus cetuximab yielding a 51% overall objective response rate in 35 evaluable patients with recurrent or metastatic head and neck squamous cell carcinoma, far surpassing the historical 2.3-month PFS of standard therapies with an overall 7.8 months. The combo proved safe, with just 6% serious adverse events and no severe neuropathy. Dose selection awaits further maturation. Yet risks loom if final results diverge.
8-K
Q2 core revenue up 16%
Fulgent Genetics reported Q2 2025 core revenue of $81.7 million, up 16% year-over-year, driven by laboratory services growth while a $9.9 million impairment charge on a prior investment pushed GAAP loss to $19.0 million. Non-GAAP income stood at $2.1 million, with cash reserves at $777.5 million. The company raised full-year core revenue guidance to $320 million, signaling momentum in diagnostics and therapeutics. Yet impairments highlight investment risks.
10-Q
Q2 FY2025 results
Fulgent Genetics posted solid Q2 revenue growth of 15% year-over-year to $81.8M, fueled by 20% gains in anatomic pathology and 73% in BioPharma services, while precision diagnostics rose 10%; gross margin expanded to 42% from 37%, yet operating loss widened slightly to $19.7M amid higher selling and administrative costs. The quarter's net loss of $19.3M included a $9.9M impairment on an equity investment, pushing it beyond operating loss due to that non-cash hit. Cash equivalents stood at $87.9M with no debt beyond minor notes payable, bolstered by $81.1M in investing inflows from security maturities. Free cash flow turned negative at $(46.1M) (derived), reflecting $34.6M operating outflow and $11.5M capex. In July 2025, Fulgent closed the ANP acquisition for $4.2M net cash plus $5.7M contingent stock, securing key patents for clinical programs. Regulatory probes linger as a key risk.
8-K
Annual meeting elects directors
Fulgent Genetics held its 2025 Annual Meeting on May 15, with 82% of shares present. Stockholders elected Ming Hsieh, Michael Nohaile, Regina Groves, and Linda Marsh as directors, though each faced notable withheld votes signaling governance concerns. They ratified Deloitte & Touche as auditors and approved executive compensation on an advisory basis. Board continuity holds firm.
8-K
Q1 core revenue surges 16%
Fulgent Genetics reported Q1 2025 core revenue of $73.5 million, up 16% year-over-year, driven by growth across laboratory services while advancing its therapeutic pipeline. Non-GAAP income hit $1.2 million, or $0.04 per share, contrasting a GAAP loss of $11.5 million, with cash reserves at $814.6 million. The company repurchased $8.7 million in shares. It reiterated full-year core revenue guidance of $310 million. Momentum builds steadily.
IPO
Employees
Sector
Industry
DGX
Quest Diagnostics Incorporated
174.78-3.50
GNTLF
GENETIC TECHNOLOGIES
1.00+0.00
IDXG
Interpace Biosciences, Inc.
1.10-0.04
ILMN
Illumina, Inc.
95.03-2.77
MYGN
Myriad Genetics, Inc.
7.91-0.22
NEO
NeoGenomics, Inc.
10.28+0.36
QGEN
Qiagen N.V.
47.19-0.76
TMO
Thermo Fisher Scientific Inc
558.31+0.68
TWST
Twist Bioscience Corporation
32.21-1.36
WGS
GeneDx Holdings Corp.
131.76-5.71